Novavax NVAX
NASDAQ NVAX
$10.89 +0.11 (+1.02%)
At close: Nov 9, 2026 · 4:00 PM EST

Novavax (NVAX) Liabilities from Discontinued Operations (2025)

Updated

Novavax's Liabilities from Discontinued Operations came in at $51.44 million for Q3 2025.

Analysis

Novavax (NVAX) Liabilities from Discontinued Operations (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn
5 Novartis Ag 316.85 Bn 290.09 Bn -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn
10 Novavax 1.80 Bn -1.06 Bn 44.81 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 51.44 Mn
API Access

Novavax Liabilities from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-from-discontinued-operations&ticker=NVAX&period=max&api_key=YOUR_API_KEY